Institute for Alternative Futures
New Report Addresses Potential Benefits and Shortcomings in Development of Risk Evaluation and Mitigation Strategies REMS
Published in Medical Letter on the CDC and FDA, April 18th, 2010
Two years after the Food and Drug Administration Amendments Act of 2007 (FDAAA) gave FDA new powers to require Risk Evaluation and Mitigation Strategies (REMS) for higher risk drugs and biologics, a new report concludes that an optimal future for REMS is possible if the agency adopts a systems approach when designing REMS programs and takes advantage of new technologies -- from electronic medical records to genetic testing -- that are changing the way medicine is practiced.
The result of a September 2009 workshop sponsored by the Society for Women's Health Research and facilitated by the Institute for Alternative Futures, the report -- Optimal Futures for Risk...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Infectious Diseases Society of America
Study finds surgical masks provided effective protection of health-care workers against H1N1 - NIH/National Institute of Allergy and Infectious Diseases
Rapid development of drug-resistant 2009 H1N1 influenza reported in 2 cases - Adenosine Therapy
Research results from Mayo Clinic update understanding of adenosine therapy - Alloimmunization
Study data from Emory University, Medical Department update understanding of alloimmunization - Arthritis
COLCRYS(R) (Colchicine, USP) Shows Superior Safety With Comparable - Breast Implants
Recent studies by J.C.S. Goes and co-authors add new data to breast implants findings - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
